BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017;5:e1080-9. [PMID: 29025631 DOI: 10.1016/S2214-109X(17)30372-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 45] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Nabity SA, Gunde LJ, Surie D, Shiraishi RW, Kirking HL, Maida A, Auld AF, Odo M, Jahn A, Nyirenda RK, Oeltmann JE. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). PLoS One 2021;16:e0248115. [PMID: 33793577 DOI: 10.1371/journal.pone.0248115] [Reference Citation Analysis]
2 Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med 2021;18:e1003875. [PMID: 34914696 DOI: 10.1371/journal.pmed.1003875] [Reference Citation Analysis]
3 Melgar M, Shiraishi RW, Tende C, Mwanza S, Mulenga J, Khondowe S, Mwakazanga D, Kapungu K, Tembo M, Nota A, Lungu P, Moore B, Podewils LJ. Assessment of the tuberculosis case-finding and prevention cascade among people living with HIV in Zambia - 2018: a cross-sectional cluster survey. BMC Public Health 2021;21:859. [PMID: 33947361 DOI: 10.1186/s12889-021-10929-z] [Reference Citation Analysis]
4 Nyathi S, Dlodlo RA, Satyanarayana S, Takarinda KC, Tweya H, Hove S, Matambo R, Mandewo W, Nyathi K, Sibanda E, Harries AD. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One 2019;14:e0223076. [PMID: 31581271 DOI: 10.1371/journal.pone.0223076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Boyd AT, Moore B, Shah M, Tran C, Kirking H, Cavanaugh JS, Al-Samarrai T, Pathmanathan I. Implementing TB preventive treatment within differentiated HIV service delivery models in global programs. Public Health Action 2020;10:104-10. [PMID: 33134124 DOI: 10.5588/pha.20.0014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2018. MMWR Morb Mortal Wkly Rep 2020;69:281-5. [PMID: 32191687 DOI: 10.15585/mmwr.mm6911a2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
7 Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang WH. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open 2019;9:e029058. [PMID: 31147370 DOI: 10.1136/bmjopen-2019-029058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019;33:525-36. [PMID: 30325773 DOI: 10.1097/QAD.0000000000002053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun 2021;2:71. [PMID: 34193311 DOI: 10.1186/s43058-021-00173-2] [Reference Citation Analysis]
10 Opollo V, Sun X, Lando R, Miyahara S, Torres TS, Hosseinipour MC, Bisson GP, Kumwenda J, Gupta A, Nyirenda M, Katende K, Suryavanshi N, Beulah F, Shah NS. The effect of TB treatment on health-related quality of life for people with advanced HIV. Int J Tuberc Lung Dis 2020;24:910-5. [PMID: 33156757 DOI: 10.5588/ijtld.19.0716] [Reference Citation Analysis]
11 Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, Peters JA, Chiume L, Flach C, Lawn SD, Fielding K. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Lancet 2018;392:292-301. [PMID: 30032978 DOI: 10.1016/S0140-6736(18)31267-4] [Cited by in Crossref: 92] [Cited by in F6Publishing: 65] [Article Influence: 23.0] [Reference Citation Analysis]
12 Bares SH, Swindells S. Latent Tuberculosis and HIV Infection. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00726-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ferguson O, Jo Y, Pennington J, Johnson K, Chaisson RE, Churchyard G, Dowdy D. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2020;23:e25623. [PMID: 33073520 DOI: 10.1002/jia2.25623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Odume B, Meribe SC, Odusote T, Ifunanya M, Debem H, Amazue-Ezeuko I, Ogbanufe O, Adamu Y, Onotu D. Taking tuberculosis preventive therapy implementation to national scale: the Nigerian PEPFAR Program experience. Public Health Action 2020;10:7-10. [PMID: 32368517 DOI: 10.5588/pha.19.0033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 N'takpe JB, Gabillard D, Moh R, Gardiennet E, Emieme A, Badje A, Kouame GM, Toni TD, Karcher S, Carrou JL, Ménan H, Danel C, Eholie SP, Rouzioux C, Anglaret X. Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts. EBioMedicine 2020;56:102815. [PMID: 32512517 DOI: 10.1016/j.ebiom.2020.102815] [Reference Citation Analysis]
17 Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, Sean Cavanaugh J. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther 2020;17:40. [PMID: 32650797 DOI: 10.1186/s12981-020-00296-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
21 Boyd AT, Lodiongo DK, Benson JM, Aragaw S, Pasquale MS, Ayalneh H, Olemukan R, Avaku I, Baabe N, Achut V, Chun H, Bunga S. Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan. Bull World Health Organ 2021;99:34-40. [PMID: 33716332 DOI: 10.2471/BLT.20.254789] [Reference Citation Analysis]
22 Churchyard GJ, Swindells S. Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. PLoS Med 2019;16:e1002787. [PMID: 31013273 DOI: 10.1371/journal.pmed.1002787] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
23 Roscoe C, Lockhart C, de Klerk M, Baughman A, Agolory S, Gawanab M, Menzies H, Jonas A, Salomo N, Taffa N, Lowrance D, Robsky K, Tollefson D, Pevzner E, Hamunime N, Mavhunga F, Mungunda H. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health 2020;20:1838. [PMID: 33261569 DOI: 10.1186/s12889-020-09902-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ, Chaisson RE, Martinson N. Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort. Clin Infect Dis 2020;71:1419-26. [PMID: 31631221 DOI: 10.1093/cid/ciz1024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Lisanwork Arage L, Deybasso HA, Yilma Gebremichael D, Gintamo Nuramo B, Negash Mekuria Z. Determinants of Drug-Induced Hepatotoxicity Among Patients with Human Immunodeficiency Virus Taking a High Dose of Rifapentine Plus Isoniazid Drugs at the All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia. HIV AIDS (Auckl) 2021;13:307-14. [PMID: 33758553 DOI: 10.2147/HIV.S300135] [Reference Citation Analysis]
26 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Escudero JN, Hawn TR, John-Stewart GC. Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children. BMJ Open 2020;10:e034308. [PMID: 31969368 DOI: 10.1136/bmjopen-2019-034308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Mukherjee TI, Hirsch-Moverman Y, Saito S, Gadisa T, Melaku Z, Howard AA. Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia. Drug Alcohol Depend 2019;204:107465. [PMID: 31499239 DOI: 10.1016/j.drugalcdep.2019.04.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Glob Public Health 2021;:1-14. [PMID: 33650939 DOI: 10.1080/17441692.2021.1892793] [Reference Citation Analysis]
29 Al-Mozaini M, Alrahbeni T, Dirar Q, Alotibi J, Alrajhi A. HIV in the Kingdom of Saudi Arabia: Can We Change the Way We Deal with Co-Infections. Infect Drug Resist 2021;14:111-7. [PMID: 33500633 DOI: 10.2147/IDR.S270355] [Reference Citation Analysis]
30 Huang Y, Zhou O, Zheng Z, Xu Y, Shao Y, Qin C, Qin F, Lai J, Liu H, Chen R, Ye L, Liang H, Qin X, Jiang J. Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study. AIDS Res Ther 2020;17:44. [PMID: 32680536 DOI: 10.1186/s12981-020-00300-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, Menzies D. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med 2021;18:e1003738. [PMID: 34520459 DOI: 10.1371/journal.pmed.1003738] [Reference Citation Analysis]
32 Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, Mecha J, Warr AJ, Kamene M, Horne DJ. Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya. BMC Infect Dis 2021;21:218. [PMID: 33632173 DOI: 10.1186/s12879-021-05916-z] [Reference Citation Analysis]
33 Affi R, Gabillard D, Kouame GM, Ntakpe JB, Moh R, Badje A, Danel C, Inwoley A, Eholié SP, Anglaret X, Weiss L. Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults. HIV Med 2022. [PMID: 35023284 DOI: 10.1111/hiv.13230] [Reference Citation Analysis]
34 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
35 MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets - 2017. MMWR Morb Mortal Wkly Rep 2019;68:263-6. [PMID: 30897077 DOI: 10.15585/mmwr.mm6811a3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 24.7] [Reference Citation Analysis]
36 Holmberg V, Soini H, Kivelä P, Ollgren J, Ristola M. Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998-2015. BMC Infect Dis 2019;19:264. [PMID: 30885144 DOI: 10.1186/s12879-019-3890-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, Jain V, Clark TD, Kwarisiima D, Petersen ML, Kamya MR, Charlebois ED, Havlir DV, Marquez C; SEARCH collaboration. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care 2020;32:119-27. [PMID: 31181961 DOI: 10.1080/09540121.2019.1619661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Jain A, Lodha R. Management of Latent Tuberculosis Infection in Children from Developing Countries. Indian J Pediatr 2019;86:740-5. [PMID: 30741387 DOI: 10.1007/s12098-019-02861-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
39 Kendall EA, Hussain H, Kunkel A, Kubiak RW, Trajman A, Menzies R, Drain PK. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis. BMC Med 2021;19:315. [PMID: 34903214 DOI: 10.1186/s12916-021-02189-w] [Reference Citation Analysis]
40 Russom M, Woldu HG, Berhane A, Jeannetot DYB, Stricker BH, Verhamme K. Effectiveness of a 6-Month Isoniazid on Prevention of Incident Tuberculosis Among People Living with HIV in Eritrea: A Retrospective Cohort Study. Infect Dis Ther. [DOI: 10.1007/s40121-022-00589-w] [Reference Citation Analysis]
41 Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV-no more excuses. Lancet Glob Health 2017;5:e1048-9. [PMID: 29025618 DOI: 10.1016/S2214-109X(17)30390-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
42 Agizew T, Chihota V, Nyirenda S, Tedla Z, Auld AF, Mathebula U, Mathoma A, Boyd R, Date A, Pals SL, Lekone P, Finlay A. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial. BMC Infect Dis 2019;19:1058. [PMID: 31842773 DOI: 10.1186/s12879-019-4697-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Nabity SA, Mponda K, Gutreuter S, Surie D, Williams A, Sharma AJ, Schnaubelt ER, Marshall RE, Kirking HL, Zimba SB, Sunguti JL, Chisuwo L, Chiwaula MJ, Gregory JF, da Silva R, Odo M, Jahn A, Kalua T, Nyirenda R, Girma B, Mpunga J, Buono N, Maida A, Kim EJ, Gunde LJ, Mekonnen TF, Auld AF, Muula AS, Oeltmann JE. Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi. Front Public Health 2020;8:551308. [PMID: 33324593 DOI: 10.3389/fpubh.2020.551308] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab319. [PMID: 34395707 DOI: 10.1093/ofid/ofab319] [Reference Citation Analysis]
45 Kagujje M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health 2019;19:1329. [PMID: 31640657 DOI: 10.1186/s12889-019-7652-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Dye C, Williams BG. Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region. Bull World Health Organ 2019;97:405-14. [PMID: 31210678 DOI: 10.2471/BLT.18.228577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
47 Sullivan A, Nathavitharana RR. Addressing TB-related mortality in adults living with HIV: a review of the challenges and potential solutions. Therapeutic Advances in Infection 2022;9:204993612210841. [DOI: 10.1177/20499361221084163] [Reference Citation Analysis]
48 Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 110] [Cited by in F6Publishing: 49] [Article Influence: 36.7] [Reference Citation Analysis]
49 Saraceni V, Benzaken AS, Pereira GFM, Andrade KB, Oliveira PB, Arakaki-Sanchez D, Caruso A, Souza FMA. Tuberculosis burden on AIDS in Brazil: A study using linked databases. PLoS One 2018;13:e0207859. [PMID: 30462733 DOI: 10.1371/journal.pone.0207859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Liou BH, Cheng CN, Lin YT, Lin YJ, Chuang YC, Lin KY, Liu WC, Lin SW, Kuo CH, Sun HY, Hung CC. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. J Int AIDS Soc 2021;24:e25844. [PMID: 34822220 DOI: 10.1002/jia2.25844] [Reference Citation Analysis]
51 Haberer JE, Bwana BM, Orrell C, Asiimwe S, Amanyire G, Musinguzi N, Siedner MJ, Matthews LT, Tsai AC, Katz IT, Bell K, Kembabazi A, Mugisha S, Kibirige V, Cross A, Kelly N, Hedt-Gauthier B, Bangsberg DR. ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa. J Int AIDS Soc 2019;22:e25232. [PMID: 30746898 DOI: 10.1002/jia2.25232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
52 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
53 Melgar M, Nichols C, Cavanaugh JS, Kirking HL, Surie D, Date A, Ahmedov S, Maloney S, Fukunaga R; CDC Country Offices’ Tuberculosis/HIV Advisors., National Ministries and Departments of Health Tuberculosis Program Managers. Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients - 16 Countries Supported by the U.S. President's Emergency Plan for AIDS Relief, 2017-2019. MMWR Morb Mortal Wkly Rep 2020;69:329-34. [PMID: 32214084 DOI: 10.15585/mmwr.mm6912a3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
54 Nabity SA, Mponda K, Gutreuter S, Surie D, Zimba SB, Chisuwo L, Moffitt A, Williams AM, Sharma AJ, Marshall RE, Chiwaula MJ, da Silva R, Kumwenda T, Chilikutali L, Mwamale S, Nagoli E, Mwenyeheri G, Ngongonda D, Kaunda E, Mtoto F, Mhango V, Mbewe K, Melgar M, Odo M, Jahn A, Buono N, Maida A, Girma B, Kalua T, Nyirenda R, Sunguti J, Woelk G, Gunde LJ, Mekonnen TF, Maphosa T, Kim EJ, Auld AF, Muula AS, Oeltmann JE. Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. The Lancet Global Health 2022;10:e705-14. [DOI: 10.1016/s2214-109x(22)00096-1] [Reference Citation Analysis]